Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies worldwide. However, the mechanisms underlying the acquisition of the metastatic potential in PDAC has not been well understood. In this study, we identified a total of 154 genes upregulated in primary tissues of PDAC with liver metastasis using the Genome Cancer Atlas (TCGA) and GSE151580 cohorts. The epithelial-mesenchymal transition and glycolysis were enriched by the liver metastasis-related genes, indicating that the liver metastasis-related genes might be functionally relevant to liver metastasis in PDAC. Moreover, we also found that the liver metastasis-related genes were primarily regulated at epigenetic level. Particularly, SFN, a cell cycle checkpoint protein, and KRT19, a marker gene for ductal cells, were predicted to be regulated by multiple methylation sites at the promoter. Clinically, we for the first time defined a liver metastasis score (LMS), which was derived from liver metastasis-related genes, and closely associated with clinical characteristics such as disease type and tumor grade, in PDAC. Furthermore, we also divided the samples into high and low LMS groups using three cohorts with long-term follow-up (TCGA, GSE71729, and E-MTAB-6134), which exhibited significantly different prognostic outcomes across three PDAC cohorts, suggesting that the LMS might be a good indicator for risk stratification in PDAC. Furthermore, we also found that the liver metastasis-related genes were primarily expressed in malignant ductal cells by integrative analysis of the bulk and single-cell gene expression data. Moreover, the malignant ductal cells and M0 macrophages were highly correlated with LMS, indicating that the two cell types might function as tumor-promoting cells in PDAC. In summary, the systematic analysis for the first time defined an LMS score to evaluate the risk of liver metastasis in PDAC and revealed that malignant ductal cells might promote PDAC liver metastasis, which greatly improves our understanding of the liver metastasis-related genes, their underlying mechanisms, and association with prognosis in PDAC.
Citation: Yang Yu, Zhe Wang, Dai hai Mo, Zhen Wang, Gang Li. Transcriptome profiling reveals liver metastasis-associated genes in pancreatic ductal adenocarcinoma[J]. Mathematical Biosciences and Engineering, 2021, 18(2): 1708-1721. doi: 10.3934/mbe.2021088
| [1] | K. E. Starkov, Svetlana Bunimovich-Mendrazitsky . Dynamical properties and tumor clearance conditions for a nine-dimensional model of bladder cancer immunotherapy. Mathematical Biosciences and Engineering, 2016, 13(5): 1059-1075. doi: 10.3934/mbe.2016030 |
| [2] | K. Renee Fister, Jennifer Hughes Donnelly . Immunotherapy: An Optimal Control Theory Approach. Mathematical Biosciences and Engineering, 2005, 2(3): 499-510. doi: 10.3934/mbe.2005.2.499 |
| [3] | OPhir Nave, Shlomo Hareli, Miriam Elbaz, Itzhak Hayim Iluz, Svetlana Bunimovich-Mendrazitsky . BCG and IL − 2 model for bladder cancer treatment with fast and slow dynamics based on SPVF method—stability analysis. Mathematical Biosciences and Engineering, 2019, 16(5): 5346-5379. doi: 10.3934/mbe.2019267 |
| [4] | Amit Kumar Roy, Priti Kumar Roy, Ellina Grigorieva . Mathematical insights on psoriasis regulation: Role of Th1 and Th2 cells. Mathematical Biosciences and Engineering, 2018, 15(3): 717-738. doi: 10.3934/mbe.2018032 |
| [5] | Peter S. Kim, Joseph J. Crivelli, Il-Kyu Choi, Chae-Ok Yun, Joanna R. Wares . Quantitative impact of immunomodulation versus oncolysis with cytokine-expressing virus therapeutics. Mathematical Biosciences and Engineering, 2015, 12(4): 841-858. doi: 10.3934/mbe.2015.12.841 |
| [6] | Atefeh Afsar, Filipe Martins, Bruno M. P. M. Oliveira, Alberto A. Pinto . A fit of CD4+ T cell immune response to an infection by lymphocytic choriomeningitis virus. Mathematical Biosciences and Engineering, 2019, 16(6): 7009-7021. doi: 10.3934/mbe.2019352 |
| [7] | Yuedan Wang, Jinke Huang, Jiaqi Zhang, Fengyun Wang, Xudong Tang . Identifying biomarkers associated with the diagnosis of ulcerative colitis via bioinformatics and machine learning. Mathematical Biosciences and Engineering, 2023, 20(6): 10741-10756. doi: 10.3934/mbe.2023476 |
| [8] | Roman Gumzej . Intelligent logistics systems in E-commerce and transportation. Mathematical Biosciences and Engineering, 2023, 20(2): 2348-2363. doi: 10.3934/mbe.2023110 |
| [9] | Bindu Kumari, Chandrashekhar Sakode, Raghavendran Lakshminarayanan, Prasun K. Roy . Computational systems biology approach for permanent tumor elimination and normal tissue protection using negative biasing: Experimental validation in malignant melanoma as case study. Mathematical Biosciences and Engineering, 2023, 20(5): 9572-9606. doi: 10.3934/mbe.2023420 |
| [10] | Alexander P. Krishchenko, Konstantin E. Starkov . The four-dimensional Kirschner-Panetta type cancer model: How to obtain tumor eradication?. Mathematical Biosciences and Engineering, 2018, 15(5): 1243-1254. doi: 10.3934/mbe.2018057 |
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies worldwide. However, the mechanisms underlying the acquisition of the metastatic potential in PDAC has not been well understood. In this study, we identified a total of 154 genes upregulated in primary tissues of PDAC with liver metastasis using the Genome Cancer Atlas (TCGA) and GSE151580 cohorts. The epithelial-mesenchymal transition and glycolysis were enriched by the liver metastasis-related genes, indicating that the liver metastasis-related genes might be functionally relevant to liver metastasis in PDAC. Moreover, we also found that the liver metastasis-related genes were primarily regulated at epigenetic level. Particularly, SFN, a cell cycle checkpoint protein, and KRT19, a marker gene for ductal cells, were predicted to be regulated by multiple methylation sites at the promoter. Clinically, we for the first time defined a liver metastasis score (LMS), which was derived from liver metastasis-related genes, and closely associated with clinical characteristics such as disease type and tumor grade, in PDAC. Furthermore, we also divided the samples into high and low LMS groups using three cohorts with long-term follow-up (TCGA, GSE71729, and E-MTAB-6134), which exhibited significantly different prognostic outcomes across three PDAC cohorts, suggesting that the LMS might be a good indicator for risk stratification in PDAC. Furthermore, we also found that the liver metastasis-related genes were primarily expressed in malignant ductal cells by integrative analysis of the bulk and single-cell gene expression data. Moreover, the malignant ductal cells and M0 macrophages were highly correlated with LMS, indicating that the two cell types might function as tumor-promoting cells in PDAC. In summary, the systematic analysis for the first time defined an LMS score to evaluate the risk of liver metastasis in PDAC and revealed that malignant ductal cells might promote PDAC liver metastasis, which greatly improves our understanding of the liver metastasis-related genes, their underlying mechanisms, and association with prognosis in PDAC.
| [1] |
R. L. Siegel, K. D. Miller, A. Jemal, Cancer statistics, 2020, CA Cancer J. Clin., 70 (2020), 7–30. doi: 10.3322/caac.21590
|
| [2] |
E. Giovannetti, C. L. van der Borden, A. E. Frampton, A. Ali, O. Firuzi, G. J. Peters, Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer, Semin. Cancer Biol., 44 (2017), 43–59. doi: 10.1016/j.semcancer.2017.04.006
|
| [3] |
C. Torres, P. J. Grippo, Pancreatic cancer subtypes: a roadmap for precision medicine, Ann. Med., 50 (2018), 277–287. doi: 10.1080/07853890.2018.1453168
|
| [4] |
H. Oweira, U. Petrausch, D. Helbling, J. Schmidt, M. Mannhart, A. Mehrabi, et al., Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis, World J. Gastroenterol., 23 (2017), 1872–1880. doi: 10.3748/wjg.v23.i10.1872
|
| [5] | K. Ohno, F. Hata, H. Nishimori, T. Yasoshima, Y. Yanai, K. Sogahata, et al., Metastatic-associated biological properties and differential gene expression profiles in established highly liver and peritoneal metastatic cell lines of human pancreatic cancer, J. Exp. Clin. Cancer Res., 22 (2003), 623–631. |
| [6] | S. Yachida, C. A. Iacobuzio-Donahue, The pathology and genetics of metastatic pancreatic cancer, Arch. Pathol. Lab. Med., 133 (2009), 413–422. |
| [7] |
A. M. Krebs, J. Mitschke, M. L. Losada, O. Schmalhofer, M. Boerries, H. Busch, et al., The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer, Nat. Cell Biol., 19 (2017), 518–529. doi: 10.1038/ncb3513
|
| [8] |
C. Moriya, H. Taniguchi, K. Miyata, N. Nishiyama, K. Kataoka, K. Imai, Inhibition of PRDM14 expression in pancreatic cancer suppresses cancer stem-like properties and liver metastasis in mice, Carcinogenesis, 38 (2017), 638–648. doi: 10.1093/carcin/bgx040
|
| [9] |
J. A. Galvan, I. Zlobec, M. Wartenberg, A. Lugli, B. Gloor, A. Perren, et al., Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer, Br. J. Cancer, 112 (2015), 1944–1950. doi: 10.1038/bjc.2015.177
|
| [10] |
H. Knaack, L. Lenk, L. M. Philipp, L. Miarka, S. Rahn, F. Viol, et al., Liver metastasis of pancreatic cancer: the hepatic microenvironment impacts differentiation and self-renewal capacity of pancreatic ductal epithelial cells, Oncotarget, 9 (2018), 31771–31786. doi: 10.18632/oncotarget.25884
|
| [11] |
V. Quaranta, C. Rainer, S. R. Nielsen, M. L. Raymant, M. S. Ahmed, D. D. Engle, et al., Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer, Cancer Res., 78 (2018), 4253–4269. doi: 10.1158/0008-5472.CAN-17-3876
|
| [12] |
H. Griesmann, C. Drexel, N. Milosevic, B. Sipos, J. Rosendahl, T. M. Gress, et al., Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer, Gut, 66 (2017), 1278–1285. doi: 10.1136/gutjnl-2015-310049
|
| [13] |
F. Runa, S. Hamalian, K. Meade, P. Shisgal, P. C. Gray, J. A. Kelber, Tumor microenvironment heterogeneity: challenges and opportunities, Curr. Mol. Biol. Rep., 3 (2017), 218–229. doi: 10.1007/s40610-017-0073-7
|
| [14] | Cancer Genome Atlas Research Network, Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma, Cancer Cell, 32 (2017), 185–203. |
| [15] |
R. A. Moffitt, R. Marayati, E. L. Flate, K. E. Volmar, S. G. Loeza, K. A. Hoadley, et al., Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma, Nat. Genet., 47 (2015), 1168–1178. doi: 10.1038/ng.3398
|
| [16] |
F. Puleo, R. Nicolle, Y. Blum, J. Cros, L. Marisa, P. Demetter, et al., Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features, Gastroenterology, 155 (2018), 1999–2013. doi: 10.1053/j.gastro.2018.08.033
|
| [17] |
J. Peng, B. F. Sun, C. Y. Chen, J. Y. Zhou, Y. S. Chen, H. Chen, et al., Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma, Cell Res., 29 (2019), 725–738. doi: 10.1038/s41422-019-0195-y
|
| [18] |
G. Yu, L. G. Wang, Y. Han, Q. Y. He, ClusterProfiler: an R package for comparing biological themes among gene clusters, OMICS, 16 (2012), 284–287. doi: 10.1089/omi.2011.0118
|
| [19] |
D. A. Barbie, P. Tamayo, J. S. Boehm, S. Y. Kim, S. E. Moody, I. F. Dunn, et al., Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1, Nature, 462 (2009), 108–112. doi: 10.1038/nature08460
|
| [20] |
A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci. U. S. A., 102 (2005), 15545–15550. doi: 10.1073/pnas.0506580102
|
| [21] |
S. Hanzelmann, R. Castelo, J. Guinney, GSVA: gene set variation analysis for microarray and RNA-seq data, BMC Bioinf., 14 (2013), 7. doi: 10.1186/1471-2105-14-7
|
| [22] | T. M. Therneau, T. Lumley, A. Elizabeth, C. Cynthia, Survival: Survival Analysis, 2020. Available from: https://cran.r-project.org/web/packages/survival/index.html. |
| [23] |
L. Phan, P. C. Chou, G. Velazquez-Torres, I. Samudio, K. Parreno. Y. Huang, et al., The cell cycle regulator 14-3-3sigma opposes and reverses cancer metabolic reprogramming, Nat. Commun., 6 (2015), 7530. doi: 10.1038/ncomms8530
|
| [24] | C. A. Rimland, S. G. Tilson, C. M. Morell, R. A. Tomaz, W. Y. Lu, S. E. Adams, et al., Regional differences in human biliary tissues and corresponding in vitro derived organoids, Hepatology, 2020 (2020). |
| [25] |
Y. Senbabaoglu, R. S. Gejman, A. G. Winer, M. Liu, E. M. Van Allen, G. de Velasco, et al., Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures, Genome Biol., 17 (2016), 231. doi: 10.1186/s13059-016-1092-z
|
| [26] |
F. Fu, S. Liu, S. Zeng, H. Shen, The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma, Mol. Cancer, 17 (2018), 62. doi: 10.1186/s12943-018-0815-z
|
| [27] |
T. Y. S. Le Large, M. F. Bijlsma, G. Kazemier, H. W. M. van Laarhoven, E. Giovannetti, C. R. Jimenez, Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies, Semin. Cancer Biol., 44 (2017), 153–169. doi: 10.1016/j.semcancer.2017.03.008
|
| [28] |
K. T. Yeung, J. Yang, Epithelial-mesenchymal transition in tumor metastasis, Mol. Oncol., 11 (2017), 28–39. doi: 10.1002/1878-0261.12017
|
| [29] |
E. Rodriguez-Aznar, L. Wiesmuller, B. Sainz, P. C. Hermann, EMT and Stemness-Key Players in Pancreatic Cancer Stem Cells, Cancers (Basel), 11 (2019), 1136. doi: 10.3390/cancers11081136
|
| [30] |
J. Yang, B. Ren, G. Yang, H. Wang, G. Chen, L. You, et al., The enhancement of glycolysis regulates pancreatic cancer metastasis, Cell. Mol. Life Sci., 77 (2020), 305–321. doi: 10.1007/s00018-019-03278-z
|
| [31] |
F. Robin, G. Angenard, L. Cano, L. Courtin-Tanguy, E. Gaignard, Z. E. Khene, et al., Molecular profiling of stroma highlights stratifin as a novel biomarker of poor prognosis in pancreatic ductal adenocarcinoma, Br. J. Cancer, 123 (2020), 72–80. doi: 10.1038/s41416-020-0863-1
|
| [32] | H. Yao, Z. Yang, Z. Liu, X. Miao, L. Yang, D. Li, et al., Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma, Cancer Biomark, 17 (2016), 397–404. |
| [33] |
M. Fornaro, R. Dell'Arciprete, M. Stella, C. Bucci, M. Nutini, M. G. Capri, et al., Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas, Int. J. Cancer, 62 (1995), 610–618. doi: 10.1002/ijc.2910620520
|
| [34] |
M. Tanaka, A. L. Mihaljevic, P. Probst, M. Heckler, U. Klaiber, U. Heger, et al., Meta-analysis of recurrence pattern after resection for pancreatic cancer, Br. J. Surg., 106 (2019), 1590–1601. doi: 10.1002/bjs.11295
|
| [35] |
M. Najafi, N. Hashemi Goradel, B. Farhood, E. Salehi, M. S. Nashtaei, N. Khanlarkhani, et al., Macrophage polarity in cancer: A review, J. Cell. Biochem., 120 (2019), 2756–2765. doi: 10.1002/jcb.27646
|
| [36] | W. Li, J. Zeng, B. Luo, Y. Mao, Y. Liang, W. Zhao, et al., High expression of activated CD4(+) memory T cells and CD8(+) T cells and low expression of M0 macrophage are associated with better clinical prognosis in bladder cancer patients, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 36 (2020), 97–103. |
 mbe-18-02-088-s001.xlsx |
 |
| mbe-18-02-088-s002.xlsx |
|
| 1. | Linkun Hu, Cheng Chen, Jun Zhang, Kerong Wu, Xuefeng Zhang, Haiyan Liu, Jianquan Hou, IL-35 Pretreatment Alleviates Lipopolysaccharide-Induced Acute Kidney Injury in Mice by Inhibiting NF-κB Activation, 2017, 40, 0360-3997, 1393, 10.1007/s10753-017-0582-9 | |
| 2. | Manouchehr Teymouri, Matteo Pirro, Francesca Fallarino, Marco Gargaro, Amirhosein Sahebkar, IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases, 2018, 143, 00207136, 2105, 10.1002/ijc.31382 | |
| 3. | Xuefen Li, Xia Liu, Weilin Wang, IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases, 2021, 9, 2296-634X, 10.3389/fcell.2021.614847 | |
| 4. | Arezoo Bassagh, Mehdi Hayatbakhsh Abasi, Tiziana Larussa, Motahareh Ghazizadeh, Maryam Nemati, Ehsan Mirkamandar, Abdollah Jafarzadeh, Diminished circulating concentration of interleukin-35 in Helicobacter pylori -infected patients with peptic ulcer: Its association with FOXP3 gene polymorphism, bacterial virulence factor CagA, and gender of patients, 2018, 23, 10834389, e12501, 10.1111/hel.12501 | |
| 5. | Lanlan Yang, Xue Shao, Shengnan Jia, Qian Zhang, Zhenjing Jin, Interleukin-35 Dampens CD8+ T Cells Activity in Patients With Non-viral Hepatitis-Related Hepatocellular Carcinoma, 2019, 10, 1664-3224, 10.3389/fimmu.2019.01032 | |
| 6. | Jing-Jing Zhu, Ning-Ning Shan, Immunomodulatory cytokine interleukin-35 and immune thrombocytopaenia, 2020, 48, 0300-0605, 030006052097647, 10.1177/0300060520976477 | |
| 7. | Ming-Xi Liu, Qing-Yu Liu, Ye Liu, Zhi-Ming Cheng, Lei Liu, Lei Zhang, Da-Hui Sun, Interleukin-35 suppresses antitumor activity of circulating CD8+ T cells in osteosarcoma patients, 2019, 60, 0300-8207, 367, 10.1080/03008207.2018.1552267 | |
| 8. | Siqi Liu, Lanlan Yang, Shengnan Jia, Rui Zhao, Zhenjing Jin, Interleukin-35 suppresses the activity of natural killer-like B cells in patients with hepatocellular carcinoma, 2021, 100, 15675769, 108161, 10.1016/j.intimp.2021.108161 | |
| 9. | Ashok Patidar, Sathishkumar Selvaraj, Mohona Chakravarti, Ipsita Guha, Avishek Bhuniya, Saurav Bera, Sukanya Dhar, Kamalika Roy, Rathindranath Baral, Debprasad Chattopadhyay, Chiranjib Pal, Bhaskar Saha, TLR induced IL-27 plays host-protective role against B16BL6 melanoma in C57BL/6 mice, 2022, 154, 10434666, 155871, 10.1016/j.cyto.2022.155871 | |
| 10. | Marta Smycz‑Kubańska, Sebastian Stępień, Joanna Gola, Celina Kruszniewska‑Rajs, Dominika Wendlocha, Patrycja Królewska‑Daszczyńska, Anna Strzelec, Jarosław Strzelczyk, Wojciech Szanecki, Andrzej Witek, Aleksandra Mielczarek‑Palacz, Analysis of CXCL8 and its receptors CXCR1/CXCR2 at the mRNA level in neoplastic tissue, as well as in serum and peritoneal fluid in patients with ovarian cance, 2022, 26, 1791-2997, 10.3892/mmr.2022.12812 | |
| 11. | Anna K. Rekowska, Karolina Obuchowska, Magdalena Bartosik, Żaneta Kimber-Trojnar, Magdalena Słodzińska, Magdalena Wierzchowska-Opoka, Bożena Leszczyńska-Gorzelak, Biomolecules Involved in Both Metastasis and Placenta Accreta Spectrum—Does the Common Pathophysiological Pathway Exist?, 2023, 15, 2072-6694, 2618, 10.3390/cancers15092618 | |
| 12. | Lina Ying, Luping Gong, Sicen Meng, Xiudi Wu, Mingcai Li, Yan Li, Circulating interleukin-39 as a potential biomarker for rheumatoid arthritis diagnosis, 2023, 00099120, 110616, 10.1016/j.clinbiochem.2023.110616 | |
| 13. | Akbar Soleimani Babadi, Arda Kiani, Esmaeil Mortaz, Kimia Taghavi, Adnan Khosravi, Majid Marjani, Sharareh Seifi, Habib Emami, Atefeh Abedini, Serum Interleukin-27 Level in Different Clinical Stages of Lung Cancer, 2019, 7, 1857-9655, 45, 10.3889/oamjms.2019.018 | |
| 14. | Abeer S. Alnahdi, Muhammad Idrees, Nonlinear dynamics of estrogen receptor-positive breast cancer integrating experimental data: A novel spatial modeling approach, 2023, 20, 1551-0018, 21163, 10.3934/mbe.2023936 | |
| 15. | Xuan Cai, Ruo‐Yun Gui, Jin Wu, Chen‐Cong Wang, Xiao‐Lu Zhu, Hai‐Xia Fu, Xiao‐Hui Zhang, Decreased Expression of IL‐35 and Its Receptor Contributes to Impaired Megakaryopoiesis in the Pathogenesis of Immune Thrombocytopenia, 2024, 2198-3844, 10.1002/advs.202305798 | |
| 16. | Nanxi Shi, Xue Xia, Yiming Chen, Yingying Ye, Xin Tang, Zhenhua Li, Bibliometrics analysis of IL-27 as a unique cytokine (2002–2023) and impact on cancer progression, 2024, 2, 2957-8701, 9340033, 10.26599/AGR.2024.9340033 | |
| 17. | Leila Kiani, Mozhdeh Momtahan, Zahra Shiravani, Abbas Ghaderi, Mohammad Javad Fattahi, Shaghayegh Moradi Alamdarloo, Atefeh Hashemi, Razieh Arman, Seyed Hamdollah Mosavat, Role of serum IL-35 levels in patients with benign and malignant primary ovarian tumors: a case-control study, 2025, 15, 2045-2322, 10.1038/s41598-025-97349-w |
Figures(5) / Tables(2)
Yang Yu, Zhe Wang, Dai hai Mo, Zhen Wang, Gang Li. Transcriptome profiling reveals liver metastasis-associated genes in pancreatic ductal adenocarcinoma[J]. Mathematical Biosciences and Engineering, 2021, 18(2): 1708-1721. doi: 10.3934/mbe.2021088
DownLoad: